# Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis

> **NCT03526900** · PHASE2 · COMPLETED · sponsor: **Spanish Lung Cancer Group** · enrollment: 40 (actual)

## Conditions studied

- Non-small Cell Lung Cancer Stage IV

## Interventions

- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03526900
- **Lead sponsor:** Spanish Lung Cancer Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-07
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-09-15
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03526900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03526900, "Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03526900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*